Sofie Elisabeth Midgley

Sofie Elisabeth Midgley

Auto-generated profile, based on publicly available information

Sofie Elisabeth Midgley

The WHO National Reference Laboratory for Poliovirus, Statens Serum Institute, DK-2300 Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2020 in Eurosurveillance
Verified
Journal Article
Open access
SMSofie Elisabeth Midgley
Sofie Elisabeth Midgley
KBKimberley Benschop
Kimberley Benschop
RDRobert Dyrdak
Robert Dyrdak
AMAudrey Mirand
Audrey Mirand
JBJean-Luc Bailly
Jean-Luc Bailly
AMAdam Meijer
Adam Meijer
Enterovirus D68 (EV-D68) was detected in 93 patients from five European countries between 1 January 2019 and 15 January 2020, a season with expected low circulation. Patients were primarily children (n = 67, median age: 4 years), 59 patients required hospitalisation and five had severe neurologic manifestations. Phylogenetic analysis revealed two clusters in the B3 subclade and subclade A2/D. This circulation of EV-D68 associated with neurological manifestations stresses the importance of surveillance and diagnostics beyond expected peak years.

27 August 2021 in Microorganisms
Verified
Journal Article
Open access
PDF file
HHHeli Harvala
Heli Harvala
KBKimberley S. M. Benschop
Kimberley S. M. Benschop
NBNataša Berginc
Nataša Berginc
SMSofie Midgley
Sofie Midgley
KWKatja C. Wolthers
Katja C. Wolthers
ONOn Behalf Of The Enpen Hospital-Based Surveillance Network
On Behalf Of The Enpen Hospital-Based Surveillance Network
Background. Non-polio enteroviruses (EVs) and human parechoviruses (PeVs) cause a wide range of human infections. Limited data on their true disease burden exist as standardized European-wide surveillance is lacking. Aims. Our aim is to estimate the disease burden of EV and PeV infections in Europe via establishment of standardized surveillance for hand, foot and mouth disease (HFMD) and respiratory and neurological infections caused by these viruses. We will also assess the sensitivity of assays implemented in the network of participating laboratories so that all EV and PeV types are adequately detected. Plan. The European Non-Polio Enterovirus Network (ENPEN) has developed standardized protocols for a prospective, multi-center and cross-sectional hospital-based pilot study. Protocols include guidance for diagnosis, case definition, detection, characterization and reporting of EV and PeV infections associated with HFMD and respiratory and neurological diseases. Over 30 sites from 17 European countries have already registered to this one pilot study, likely to be commenced in 2022. Benefits. This surveillance will allow European-wide comparison of data on EV and PeV infection. These data will also be used to determine the burden of EV and PeV infections, which is needed to guide the further prevention measures and policies.

1 August 2017 in Journal of Clinical Virology
Verified
Journal Article
Closed access
CBCéline Barnadas
Céline Barnadas
SMSofie E. Midgley
Sofie E. Midgley
MSMarianne N. Skov
Marianne N. Skov
LJLotte Jensen
Lotte Jensen
MPMille W. Poulsen
Mille W. Poulsen
TFThea Koelsen Fischer
Thea Koelsen Fischer

29 June 2017 in Eurosurveillance
Verified
Journal Article
Open access
SMSofie E Midgley
Sofie E Midgley
ANAstrid G Nielsen
Astrid G Nielsen
RTRamona Trebbien
Ramona Trebbien
MPMille W. Poulsen
Mille W. Poulsen
PAPeter H Andersen
Peter H Andersen
TFThea Koelsen Fischer
Thea Koelsen Fischer
In Europe, enterovirus A71 (EV-A71) has primarily been associated with sporadic cases of neurological disease. The recent emergence of new genotypes and larger outbreaks with severely ill patients demonstrates a potential for the spread of new, highly pathogenic EV-A71 strains. Detection and characterisation of these new emerging EV variants is challenging as standard EV assays may not be adequate, necessitating the use of whole genome analysis.